Research Report on China's Diabetes Drug Market, 2013-2017
Diabetes refers to a series of metabolic disorder syndrome such as sugars, proteins, fat, water and electrolyte that are triggered by islet dysfunction and insulin resistance, and the latter is caused by the actions of various pathogenic factors such as genetic factors, immune disorders, microbial infections and their toxins, free radical toxins, psychological factors on body. In recent years, with the development of China's economy and improvement in people's living standards, the incidence and morbidity rates of diabetes also present the increasing trend year by year.
In China, with the aggravation of aging degree, improvement in living standards and increase in obese groups caused by unhealthy lifestyles, the prevention and treatment of diabetes are increasingly severe. Since China carried out the first survey on diabetes epidemiology in 1980, the morbidity rate of diabetes increases from less than 1% then to about 10% currently. Following tumors and cardiovascular diseases, diabetes becomes the third-largest chronic disease severely threatening people's health. In 1994, diabetics only accounted for 2.5% of the population in China. This figure increased to 5.5% in 2002 and 9.7% in 2008.
In China, the diabetes morbidity rate of people aged above 20 has reached over 9.7%, and the morbidity rate of pre-diabetes (impaired fasting glucose and impaired glucose tolerance) has reached 15.5%. In developed regions of China, diabetics in the rural population are far less than that in the urban population. However, the morbidity rate of pre-diabetes, i.e., impaired glucose regulation, in the rural population is higher than that in the urban population, whether in developed or economically-backward areas. In economically-developed regions, the diabetes morbidity rate of the urban population is 13.6%, and that of the rural population is 16.6%. In medium-developed regions, the diabetes morbidity rate of the urban population is 15.6%, and that of the rural population is 20%. This also shows that, with the development of economy and changes in lifestyles, the rural population are potential groups who are more likely to suffer from diabetes.
Drug treatment is the focus of the treatment of diabetes. In addition to a small part of patients with type II diabetes which can be controlled through diet therapy and exercise therapy, the rest all need drug treatment. Diabetes drugs include Chinese patent drugs and western drugs, of which the latter is in a dominant position, while the former is in an auxiliary position in the treatment of diabetes.
With the increase in diabetes morbidity rate, residents' income levels and medical levels, the market size of China's diabetes drugs rises year by year, which always presents a rapidly growing trend in recent years, reaching CNY 15.86 billion in 2011, with an increase of 18.2% YOY.
In China, insulin preparations are always leaders in diabetes drug market, and the market share grows year by year recently, reaching 37.75% in 2011, with promising market prospects. Acarbose ranked the second. Before 2010, the share declined year after year, which slightly rebounded in 2011. Market shares of other varieties are all very low, which cannot threaten the market positions of insulin preparations and Acarbose.
The market size of China's diabetes drugs is expected to maintain an annual growth rate of over 18% from 2013 to 2017.
More following information can be acquired through this report:
In China, with the aggravation of aging degree, improvement in living standards and increase in obese groups caused by unhealthy lifestyles, the prevention and treatment of diabetes are increasingly severe. Since China carried out the first survey on diabetes epidemiology in 1980, the morbidity rate of diabetes increases from less than 1% then to about 10% currently. Following tumors and cardiovascular diseases, diabetes becomes the third-largest chronic disease severely threatening people's health. In 1994, diabetics only accounted for 2.5% of the population in China. This figure increased to 5.5% in 2002 and 9.7% in 2008.
In China, the diabetes morbidity rate of people aged above 20 has reached over 9.7%, and the morbidity rate of pre-diabetes (impaired fasting glucose and impaired glucose tolerance) has reached 15.5%. In developed regions of China, diabetics in the rural population are far less than that in the urban population. However, the morbidity rate of pre-diabetes, i.e., impaired glucose regulation, in the rural population is higher than that in the urban population, whether in developed or economically-backward areas. In economically-developed regions, the diabetes morbidity rate of the urban population is 13.6%, and that of the rural population is 16.6%. In medium-developed regions, the diabetes morbidity rate of the urban population is 15.6%, and that of the rural population is 20%. This also shows that, with the development of economy and changes in lifestyles, the rural population are potential groups who are more likely to suffer from diabetes.
Drug treatment is the focus of the treatment of diabetes. In addition to a small part of patients with type II diabetes which can be controlled through diet therapy and exercise therapy, the rest all need drug treatment. Diabetes drugs include Chinese patent drugs and western drugs, of which the latter is in a dominant position, while the former is in an auxiliary position in the treatment of diabetes.
With the increase in diabetes morbidity rate, residents' income levels and medical levels, the market size of China's diabetes drugs rises year by year, which always presents a rapidly growing trend in recent years, reaching CNY 15.86 billion in 2011, with an increase of 18.2% YOY.
In China, insulin preparations are always leaders in diabetes drug market, and the market share grows year by year recently, reaching 37.75% in 2011, with promising market prospects. Acarbose ranked the second. Before 2010, the share declined year after year, which slightly rebounded in 2011. Market shares of other varieties are all very low, which cannot threaten the market positions of insulin preparations and Acarbose.
The market size of China's diabetes drugs is expected to maintain an annual growth rate of over 18% from 2013 to 2017.
More following information can be acquired through this report:
- Incidence of Diabetes in China
- Market Situation of China's Hospital-use Diabetes Drugs
- Competition in China's Diabetes Drug Market
- Development Trends of Diabetes Treatment Technologies and Market in China
- Diabetes Drug Manufacturers
- Pharmaceutical Trade Enterprises and Hospitals
- Investors/Research Institutions Focusing on Diabetes Drugs
1 OVERVIEW ON DIABETES DRUG MARKET
1.1 Analysis on Diabetes Epidemiology
1.2 Brief Introduction and Classification of Diabetes Drugs
2 GLOBAL DIABETES DRUG MARKET
2.1 New Diabetes Drugs Approved by U.S. FDA, 2011
2.2 Overview on Global Diabetes Drug Market
3 OVERALL DIABETES DRUG MARKET IN CHINA
3.1 Market Size of China's Hospital-use Diabetes Drugs
3.2 Market Shares of Major Varieties of Hospital-use Diabetes Drugs
3.3 Market Shares of Diabetes Drug Manufacturers in Hospital-use Drugs
3.4 Concentration Rate of Diabetes Drug Market
3.5 Growth Rates of Major Varieties in Hospital-use Diabetes Drug Market
4 ANALYSIS ON MAJOR VARIETIES IN DIABETES DRUG MARKET
4.1 Insulin Preparations
4.2 Acarbose
4.3 Metformin
4.4 Repaglinide
4.5 Glimepiride
4.6 Rosiglitazone
4.7 Gliclazide
4.8 Gliquidone
4.9 Nateglinide
4.10 Glipizide
4.11 Others
5 MAJOR DIABETES DRUGS AND PRICES IN CHINA, 2012
6 DEVELOPMENT TRENDS OF DIABETES DRUGS
6.1 Market Size Trend
6.2 Technology Trend
1.1 Analysis on Diabetes Epidemiology
1.2 Brief Introduction and Classification of Diabetes Drugs
2 GLOBAL DIABETES DRUG MARKET
2.1 New Diabetes Drugs Approved by U.S. FDA, 2011
2.2 Overview on Global Diabetes Drug Market
3 OVERALL DIABETES DRUG MARKET IN CHINA
3.1 Market Size of China's Hospital-use Diabetes Drugs
3.2 Market Shares of Major Varieties of Hospital-use Diabetes Drugs
3.3 Market Shares of Diabetes Drug Manufacturers in Hospital-use Drugs
3.4 Concentration Rate of Diabetes Drug Market
3.5 Growth Rates of Major Varieties in Hospital-use Diabetes Drug Market
4 ANALYSIS ON MAJOR VARIETIES IN DIABETES DRUG MARKET
4.1 Insulin Preparations
4.2 Acarbose
4.3 Metformin
4.4 Repaglinide
4.5 Glimepiride
4.6 Rosiglitazone
4.7 Gliclazide
4.8 Gliquidone
4.9 Nateglinide
4.10 Glipizide
4.11 Others
5 MAJOR DIABETES DRUGS AND PRICES IN CHINA, 2012
6 DEVELOPMENT TRENDS OF DIABETES DRUGS
6.1 Market Size Trend
6.2 Technology Trend
SELECTED CHARTS
Chart Market Size of Global Diabetes Drugs, 2007-2011
Chart Diabetes Drugs in Global Bestselling Drugs, 2011
Chart Market Size of China's Hospital-use Diabetes Drugs, 2007-2012
Chart Top 20 Hospital-use Diabetes Drugs by Marker Share in China, 2007-2011
Chart Top 20 Hospital-use Diabetes Drug Manufactures by Market Share in China, 2007-2011
Chart Market Concentration Rate of China's Hospital-use Diabetes Drugs, 2007-2011
Chart Market Growth Rates of Top 20 Varieties of Hospital Diabetes Drugs in China, 2008-2011
Chart Market Size of China's Insulin Preparations in Hospital-use Drugs, 2007-2011
Chart Market Shares of China's Insulin Preparation Manufacturers in Hospital-use Drugs, 2011
Chart Market Shares of China's Acarbose Enterprises in Hospital-use Drugs, 2011
Chart Market Shares of China's Metformin Manufacturers in Hospital-use Drugs, 2011
Chart Market Shares of China's Repaglinide Manufacturers in Hospital-use Drugs, 2011
Chart Prediction on Market Size of China's Anti-diabetic Hospital-use Drugs, 2013-2017
Chart Market Size of Global Diabetes Drugs, 2007-2011
Chart Diabetes Drugs in Global Bestselling Drugs, 2011
Chart Market Size of China's Hospital-use Diabetes Drugs, 2007-2012
Chart Top 20 Hospital-use Diabetes Drugs by Marker Share in China, 2007-2011
Chart Top 20 Hospital-use Diabetes Drug Manufactures by Market Share in China, 2007-2011
Chart Market Concentration Rate of China's Hospital-use Diabetes Drugs, 2007-2011
Chart Market Growth Rates of Top 20 Varieties of Hospital Diabetes Drugs in China, 2008-2011
Chart Market Size of China's Insulin Preparations in Hospital-use Drugs, 2007-2011
Chart Market Shares of China's Insulin Preparation Manufacturers in Hospital-use Drugs, 2011
Chart Market Shares of China's Acarbose Enterprises in Hospital-use Drugs, 2011
Chart Market Shares of China's Metformin Manufacturers in Hospital-use Drugs, 2011
Chart Market Shares of China's Repaglinide Manufacturers in Hospital-use Drugs, 2011
Chart Prediction on Market Size of China's Anti-diabetic Hospital-use Drugs, 2013-2017
